Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010:2:135-40.
doi: 10.2147/hiv.s6366. Epub 2010 Jun 18.

An update on the use of Atripla in the treatment of HIV in the United States

Michael A Horberg  1 , Daniel B Klein
Affiliations

An update on the use of Atripla in the treatment of HIV in the United States

Michael A Horberg et al. HIV AIDS (Auckl). 2010.

Abstract

Atripla(®) (Gilead Sciences Inc, Foster City, CA, USA and Bristol-Myers Squibb, New York City, NY, USA) is a coformulated single pill composed of efavirenz, emtricitabine, and tenofovir disoproxil, intended as a once-daily potent combination antiretroviral therapeutic agent. Its efficacy is equivalent to the 3 component drugs taken in a combination as single medications. The coformulated antiretroviral regimen can be quite effective in patients whose human immunodeficiency virus is sensitive to all 3 components of Atripla. However, women at risk of pregnancy, already pregnant, or nursing mothers should not take Atripla, due to the teratogenic potential of the efavirenz moiety. Adverse effects are similar to those seen with the constituent medications, including potential central nervous system effects and renal toxicity. Since its US Food and Drug administration approval, prescriptions for Atripla have increased steadily.

Keywords: antiretroviral therapy; efavirenz; emtricitabine; tenofovir.

PubMed Disclaimer

References

    1. Bangsberg DR, Charlebois ED, Grant RM, et al. High levels of adherence do not prevent accumulation of HIV drug resistance mutations. AIDS. 2003;17(13):1925–1932. - PubMed
    1. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133(1):21–30. - PubMed
    1. Bangsberg DR, Kroetz DL, Deeks SG. Adherence-resistance relationships to combination HIV antiretroviral therapy. Curr HIV/AIDS Rep. 2007;4(2):65–72. - PubMed
    1. Chesney M. Adherence to HAART regimens. AIDS Patient Care STDS. 2003;17(4):169–177. - PubMed
    1. Chesney MA. Factors affecting adherence to antiretroviral therapy. Clin Infect Dis. 2000;30( Suppl 2):S171–S176. - PubMed

LinkOut - more resources